| Isentress (raltegravir) / Merck (MSD) |
| Completed | N/A | 400 | Europe | | Università Vita-Salute San Raffaele, Ospedale San Raffaele | HIV Infections | 10/12 | 12/12 | | |
NCT00618371: Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia |
|
|
| Completed | N/A | 10 | US | Raltegravir (MK-0518), MK-0518 | University of Pittsburgh, National Cancer Institute (NCI) | HIV Infection | 03/09 | 03/09 | | |
| Completed | N/A | 14 | US | Raltegravir, Isentress | Stanford University | HIV Infections | 03/09 | 12/10 | | |
| Completed | N/A | 442 | US | raltegravir | Community Research Initiative of New England | HIV Infections | 06/09 | 06/09 | | |
NCT01061957: Raltegravir Treatment in Patients Failing Highly Active Antiretroviral Therapy (HAART) in Denmark |
|
|
| Completed | N/A | 96 | Europe | | Rigshospitalet, Denmark, Merck Sharp & Dohme LLC | HIV Infections | 07/09 | 12/09 | | |
| Completed | N/A | 4 | NA | | University of California, San Diego, Merck Sharp & Dohme LLC | HIV Infections | 07/09 | 02/11 | | |
NCT00774683: A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women |
|
|
| Completed | N/A | 1 | US | Raltegravir (Isentress®), ISENTRESS, MK-0518 | Kristine Patterson, MD, Merck Sharp & Dohme LLC | HIV, AIDS | 09/09 | 09/09 | | |
NCT00709397: HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy |
|
|
| Terminated | N/A | 3 | US | blood drawing | Brigham and Women's Hospital, Merck Sharp & Dohme LLC | HIV-1 Infection | 12/09 | 12/09 | | |
PLUS, NCT00884793: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut |
|
|
| Completed | N/A | 8 | US | raltegravir, Isentress, Study NNRTI, efavirenz (Sustiva), etravirine (Intelence, Study PI, atazanavir (Reyataz, ATV), fosamprenavir (Lexiva, FPV, Telzir), lopinavir/ritonavir (Kaletra, LPV/r) | University of California, San Francisco | HIV Infections | 12/09 | 12/10 | | |
NCT00858962: Buprenorphine/Raltegravir Pharmacokinetic Interaction Study |
|
|
| Completed | N/A | 12 | US | Raltegravir, Isentress | Yale University, National Institute on Drug Abuse (NIDA), Merck Sharp & Dohme LLC | HIV Infection, HIV Infections | 12/09 | 12/09 | | |
Switch-ER, NCT00944957: Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz |
|
|
| Unknown status | N/A | 60 | Europe | Raltegravir for the first 2 weeks, Efavirenz for the last 2 weeks, Efavirenz for the first 2 weeks, Raltegravir for the last 2 weeks | University Hospital, Geneva, University of Bern, University of Lausanne Hospitals, Hospital Lugano, University Hospital, Basel, Switzerland, Hospital of Neuchâtel, University Hospital, Zürich | Sleep Disorders, HIV Infections | 12/09 | 04/10 | | |
RAL-dyn, NCT00787774: Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression |
|
|
| Unknown status | N/A | 20 | Europe | resume raltegravir | Hospital Clinic of Barcelona | HIV Infection | 01/10 | 01/10 | | |
NCT00961272: Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women |
|
|
| Completed | N/A | 6 | US | | Kristine Patterson, MD, Merck Sharp & Dohme LLC | HIV Infections | 02/10 | 02/10 | | |
| Withdrawn | N/A | 0 | US | Efavirenz + Tenofovir DF/Emtricitabine, Sustiva, EFV, Tenofovir, Tenofovir Disoproxil Fumarate, TDF, Emtriva, FTC, Truvada, Atripla, Nucleoside Reverse Transcriptase Inhibitor, NRTI, Non-Nucleoside Reverse Transcriptase Inhibitor, NNRTI, Raltegravir + Tenofovir DF/Emtricitabine, Isentress, MK-0518, Integrase Inhibitor, Colonoscopy with biopsies, Colonoscopy, Biopsy, Secondary, Lymphatic, Tissue, Gastrointestinal, GALT, Peyers, Patch, Lamina, Propria, Inguinal Lymph Node Excision, Inguinal, Lymph, Node, LN, Excision | University of Minnesota, Merck Sharp & Dohme LLC | HIV Infection, HIV Infections | 03/10 | 03/11 | | |
| Completed | N/A | 200 | Europe | Raltegravir, Isentress | University of Zurich, Swiss HIV Cohort Study, Merck Sharp & Dohme LLC | HIV Infection | 04/10 | 12/11 | | |
NCT01190124: Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients |
|
|
| Completed | N/A | 151 | Europe | | Doroana, Maria Manuela, M.D., Merck Sharp & Dohme LLC, Eurotrials Brasil Consultores Cientificos Ltda | HIV Infections | 07/10 | 07/10 | | |
NCT00661960: Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy |
|
|
| Completed | N/A | 25 | US | raltegravir, Isentress, efavirenz, Sustiva | University of California, Davis | HIV Infections, AIDS | 09/10 | 07/11 | | |
NCT00672932: Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients |
|
|
| Completed | N/A | 18 | US | raltegravir, Isentress | University of California, San Francisco, National Institute of Mental Health (NIMH), Merck Sharp & Dohme LLC | HIV Infections | 10/10 | 02/11 | | |
NCT00797381: Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia |
|
|
| Unknown status | N/A | 100 | RoW | | Shanghai Public Health Clinical Center, Merck Sharp & Dohme LLC | HIV Infection, Hemophilia A | 10/10 | 05/11 | | |
| Completed | N/A | 20 | US | change from tenofovir to raltegravir, Isentress | Metropolis Medical, Merck Sharp & Dohme LLC | HIV Infections, Proteinuria | 12/10 | 06/11 | | |
NCT01066065: Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients |
|
|
| Unknown status | N/A | 120 | Europe | | Hospital Carlos III, Madrid | Cardiovascular Disease, HIV Infections | 01/11 | 01/11 | | |
| Unknown status | N/A | 20 | Europe | | Centre Hospitalier Universitaire de Nice | HIV Infection | 01/11 | 03/11 | | |
NCT00738569: Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen |
|
|
| Completed | N/A | 30 | US | Raltegravir, Brand name is Isentress | National Jewish Health, Merck Sharp & Dohme LLC | HIV | 02/11 | 02/11 | | |
PINT, NCT00641641: The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection |
|
|
| Completed | N/A | 16 | RoW | Tenofovir + emtricitabine + raltegravir., TDF, FTC, RAL | Kirby Institute, Merck Sharp & Dohme LLC | HIV Infection | 03/11 | 06/11 | | |
NCT01168167: Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation |
|
|
| Completed | N/A | 20 | Europe | | Christoph Stephan, University Hospital Heidelberg | HIV-1 | 03/11 | 05/12 | | |
Ral'inNONB, NCT01162538: To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients |
|
|
| Unknown status | N/A | 60 | Europe | | Centre Hospitalier Intercommunal Robert Ballanger | Evaluated, Non B Subtype, Naive Patients | 03/11 | 03/12 | | |
NCT01214486: Measurement of Plasma and Intracellular Concentrations of Raltegravir |
|
|
| Completed | N/A | 12 | US | Raltegravir, RAL, Isentress | University of Nebraska | HIV | 04/11 | 06/11 | | |
RALDAR, NCT01258374: Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients. |
|
|
| Completed | N/A | 15 | Europe | Raltegravir, Isentress, Darunavir, Prezista, Norvir. | Hospital Clinic of Barcelona | Integrase Inhibitors, HIV; HIV PROTEASE INHIB | 05/11 | 12/11 | | |
NCT00745368: Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women |
|
|
| Completed | N/A | 28 | US | Raltegravir | University of Rochester, Merck Sharp & Dohme LLC | HIV Infections | 06/11 | 06/11 | | |
NCT00749580: A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen |
|
|
| Completed | N/A | 46 | US | Switch NRTIs as a Backbone to Raltegravir | University of South Florida, Merck Sharp & Dohme LLC, St. Joseph's Hospital, Florida | Virus Diseases, HIV | 07/11 | 07/11 | | |
NCT01045265: Concentrations of Raltegravir in the Semen of HIV-Infected Men |
|
|
| Completed | N/A | 16 | Canada | Seminal plasma pharmacokinetics | Canadian Immunodeficiency Research Collaborative | HIV | 09/11 | 07/12 | | |
NCT01251601: The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters |
|
|
| Withdrawn | N/A | 0 | NA | Pharmacokinetics | University of North Carolina, Chapel Hill, Merck Sharp & Dohme LLC | HIV, Pregnancy | 09/11 | 09/11 | | |
NCT01042652: A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance |
|
|
| Unknown status | N/A | 60 | RoW | Raltegravir | Centers for Disease Control and Prevention, China, Merck Sharp & Dohme LLC | HIV, HIV Infections | 01/12 | 06/12 | | |
SPARE, NCT01294761: Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir |
|
|
| Completed | N/A | 59 | Japan | Raltegravir, Darunavir/r, NRTI sparing regimen | National Center for Global Health and Medicine, Japan, Ministry of Health, Labour and Welfare, Japan | HIV Infections | 02/12 | 12/13 | | |
NCT00689910: Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum |
|
|
| Withdrawn | N/A | 0 | US | | University of California, San Francisco, Merck Sharp & Dohme LLC | HIV Infections | | | | |
| Completed | N/A | 11 | US | ARV regimen chosen by treating physician, Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine), Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV, Emtricitabine: FTC, Emtriva, Abacivir: Ziagen, Tenofovir: TDF, Viread, Efavirenz: Sustiva, Stocrin, Lopinavir/Ritonavir: Kaletra, Aluvia, Atazanavir: Reyataz, Ritonavir: Norvir, Maraviroc: Selzentry, Raltegravir: MK-0518, Isentress, Etravirine: TMC-125, Intelence | Kristine Patterson, MD, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 05/12 | 05/12 | | |
NCT01318096: Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients |
|
|
| Unknown status | N/A | 60 | RoW | raltegravir and tenofovir and lamivudine, raltegravir: Isentress, efavirenz+tenofovir+lamivudine, efavirenz: Sustiva | Yunnan AIDS Care Center | HBV Coinfection, HIV Infections | 07/12 | 09/13 | | |
NCT00734344: Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection |
|
|
| Completed | N/A | 18 | US | Raltegravir, Efavirenz, Emtricitibine, Tenofovir disoproxil once daily, Tenofovir disoproxil twice daily | University of Alabama at Birmingham, Merck Sharp & Dohme LLC | Acute HIV Infection | 08/12 | 09/12 | | |
RACING, NCT01048671: Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) |
|
|
| Completed | N/A | 482 | Europe | Raltegravir, Isentress, ARV (non-raltegravir) | Merck Sharp & Dohme LLC | HIV Infections | 12/12 | 12/12 | | |
NCT01327482: Levels of Raltegravir in the Female Genital Tissue |
|
|
| Completed | N/A | 10 | US | Raltegravir, Isentress | University of Washington, Merck Sharp & Dohme LLC | HIV | 12/12 | | | |
NCT01381328: GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance |
|
|
| Unknown status | N/A | 100 | Europe | | Università Vita-Salute San Raffaele, IRCCS San Raffaele, Merck Sharp & Dohme LLC | HIV-1 Infected Patients, Fold-change Resistance, Resistance Mutations | 03/13 | 09/13 | | |
NCT00814879: Pilot Study of a Raltegravir Based NRTI Sparing Regimen |
|
|
| Completed | N/A | 60 | US | Raltegravir, Isentress, Atazanavir, Reyataz, Standard treatment regimen | Yale University, Bristol-Myers Squibb, Merck Sharp & Dohme LLC | Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections | 05/13 | 11/13 | | |
NCT00851799: Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters |
|
|
| Completed | N/A | 334 | US | Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 06/13 | 06/13 | | |
| Unknown status | N/A | 30 | US | Raltegravir | Southern California Institute for Research and Education, Merck Sharp & Dohme LLC | HIV Infection | 06/13 | 06/13 | | |
NCT01293123: Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals |
|
|
| Terminated | N/A | 2 | US | Raltegravir, tenofovir disoproxil fumarate 300 mg PO once daily, emtricitabine 200 mg PO once daily, Efavirenz | University of California, San Diego, Merck Sharp & Dohme LLC | HIV | 06/13 | 12/13 | | |
NCT01456962: Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract |
|
|
| Completed | N/A | 36 | US | | University of Colorado, Denver | Women's Health, HIV Infection, Genital Diseases, Female | 08/13 | 08/13 | | |
NCT01814722: Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266) |
|
|
| Terminated | N/A | 63 | NA | | Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 10/13 | 10/13 | | |
NCT00977756: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults |
|
|
| Completed | N/A | 168 | US | Raltegravir (RAL), Isentress, Atazanavir (ATV), Reyataz, Ritonavir (RTV), Norvir, Tenofovir (TDF), Viread, Etravirine (ETV), Intelence, Darunavir (DRV), Prezista, Maraviroc (MVC), Selzentry, Lopinavir/ritonavir (LPV/r), Kaletra | International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 03/14 | 03/14 | | |
NCT01597180: Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir |
|
|
| Withdrawn | N/A | 0 | US | | University of North Carolina, Chapel Hill, Merck Sharp & Dohme LLC | HIV | 03/14 | 03/14 | | |
NCT01078233: Observational Data Analysis in EuroSIDA (MK-0518-058) |
|
|
| Completed | N/A | 6617 | NA | | Merck Sharp & Dohme LLC, EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP) | HIV-1 Infections | 03/14 | 03/14 | | |
| Completed | N/A | 996 | RoW | | Merck Sharp & Dohme LLC | HIV Infection, HIV Infections | 05/14 | 05/14 | | |
| Completed | N/A | 7 | US | Raltegravir and Maraviroc in combination, Raltegravir (Isentress), Maraviroc(Selzentry) | University of Maryland, Baltimore, Merck Sharp & Dohme LLC | HIV Infections | 05/14 | 05/14 | | |
| Completed | N/A | 46 | RoW | Standard HIV prevention messages, BI: Information-Motivation-Behavioral Skills Model, Raltegravir, Isentress, RAL, emtricitabine/tenofovir disoproxil fumarate, Truvada, FTC/TDF | University of North Carolina, Chapel Hill | HIV | 07/14 | 07/14 | | |
NCT01078246: Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268) |
|
|
| Completed | N/A | 7124 | NA | | Merck Sharp & Dohme LLC, Kaiser Permanente | HIV-1 Infections | 12/14 | 12/14 | | |
NCT01213316: A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) |
|
|
| Completed | N/A | 451 | Europe | Raltegravir, ISENTRESS® | Merck Sharp & Dohme LLC | HIV-1 Infection | 04/15 | 04/15 | | |
NCT02218320: Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults |
|
|
| Completed | N/A | 20 | US | Raltegravir, Isentress ®, Dolutegravir, Tivicay ®, Colonoscopy with biopsy | University of North Carolina, Chapel Hill, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 10/15 | 10/15 | | |
NCT01844310: Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection |
|
|
| Unknown status | N/A | 300 | RoW | RAL+TDF+LPV/r, 3TC+TDF+LPV/r | Peking Union Medical College | AIDS/HIV PROBLEM | 12/15 | 12/15 | | |
NCT02302950: A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas |
|
|
| Unknown status | N/A | 254 | US | raltegravir, issentress | The University of Texas Health Science Center, Houston | HIV Infection | 12/15 | 12/17 | | |
RALNOVO, NCT02611895: Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy |
|
|
| Completed | N/A | 120 | Europe | HIV DNA | University Hospital, Montpellier, Institute of Human Genetics, France | HIV-1 Infection | 03/16 | 12/16 | | |
NCT00377065: Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) |
|
|
| Approved for marketing | N/A | | US | raltegravir, MK0518, ISENTRESS™ | Merck Sharp & Dohme LLC | HIV Infections | | | | |
NCT01978743: Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen |
|
|
| Completed | N/A | 10 | US | Raltegravir, Raltegravir (Isentress) 400mg BID | Massachusetts General Hospital, Merck Sharp & Dohme LLC | HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity | 09/16 | 01/17 | | |
RalAge, NCT02765776: An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens in Aged HIV Patients |
|
|
| Completed | N/A | 90 | NA | Observational retrospective cohort to describe RAL data | Azienda Policlinico Umberto I, University of Roma La Sapienza | HIV | 09/16 | 12/16 | | |
NCT02708342: Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL) |
|
|
| Completed | N/A | 100 | NA | | IRCCS San Raffaele, Merck Sharp & Dohme LLC | HIV | 11/16 | 12/16 | | |
KIRAL, NCT03158077: Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection |
|
|
| Completed | N/A | 467 | Europe | | Fundacion SEIMC-GESIDA | HIV Infections | 04/17 | 04/17 | | |
NCT01793467: Transplantation and the Use of Raltegravir in HIV-Infected Patients |
|
|
| Completed | N/A | 17 | US | | Duke University, Merck Sharp & Dohme LLC | HIV Positive, Organ Transplant Recipient, Active Wait Listing for Organ Transplant | 06/17 | 06/17 | | |
NCT01828073: Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants |
|
|
| Completed | N/A | 40 | US, RoW | Raltegravir, RAL | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 04/18 | 04/18 | | |
| Completed | N/A | 360 | Europe | Collection of data | Asociacion para el Estudio de las Enfermedades Infecciosas, Merck Sharp & Dohme LLC | Comorbidities, HIV/AIDS | 06/18 | 06/18 | | |
ETRALQD, NCT03369743: Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD) |
|
|
| Completed | N/A | 125 | Europe | | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | HIV Infections | 06/18 | 12/19 | | |
RAL-LT-HIV, NCT02995824: Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients |
|
|
| Completed | N/A | 271 | NA | Raltegravir-based antiretroviral therapy | Hospital Clinic of Barcelona | Liver Transplantation, HIV Infections, Antiretroviral Therapy | 12/19 | 12/19 | | |
| Terminated | N/A | 152 | RoW | HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID) | University of Washington, Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal, Centre de Sante de Ziguinchor, Casamance, Senegal, Janssen Pharmaceutica, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-2 Infection | 05/20 | 05/20 | | |
NCT00042289: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy |
|
|
| Completed | N/A | 1578 | US, RoW | atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4 | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 09/20 | 09/20 | | |
RalAge2, NCT03579485: An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge) |
|
|
| Recruiting | N/A | 90 | Europe | | Azienda Policlinico Umberto I | Hiv | 12/23 | 12/24 | | |
EPPICC, NCT05751031: Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration |
|
|
| Recruiting | N/A | 1200 | Europe, RoW | Raltegravir | Fondazione Penta UK, UCL Great Ormond Street Institute of Child Health | HIV Infections | 02/24 | 02/24 | | |
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study |
|
|
| Recruiting | N/A | 2017 | Europe | Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen | University of Zurich | HIV Infections | 01/25 | 01/25 | | |
